A Study of Vinflunine in Patients With Gastric Cancer

Inclusion Criteria: Patients with locally advanced or metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction who have progressed on a fluoropyrimidine or taxane-containing regimen in any combination in one prior first line treatment. EGOC performance status of 0,1 or 2 Men and women, 18 years of age and older Exclusion Criteria: Patients having received more than one previous systemic chemotherapy regimen in any setting. Major abdominal surgery within 2 months or any other surgery under general anesthesia within 4 weeks Unresolved occlusive or sub-occlusive intestinal disease or any significant chronic intestinal disease (e.g. ulcerative colitis) Prior radiation to >=30% of the bone marrow and/or radiation within 4 weeks prior to enrollment Acute or chronic hepatitis Known HIV infection A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms A history of additional risk factors for Torsade de Pointes (e.g., heart failure hypokalemia, family history of Long QT Syndrome)